Alkermes plc Acquires Avadel Pharmaceuticals plc
February 12, 2026
Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.
- Buyers
- Alkermes plc
- Targets
- Avadel Pharmaceuticals plc
- Sellers
- Avadel Pharmaceuticals plc shareholders
- Industry
- Pharmaceuticals
- Location
- Ireland
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.